Evidence map›Paper›PMID 22158476›Full record

ArticleCell death & disease2011

Cyclic AMP induces IPC leukemia cell apoptosis via CRE-and CDK-dependent Bim transcription.

S Huseby, G Gausdal, T J Keen, E Kjærland, C Krakstad, L Myhren, K Brønstad, C Kunick, F Schwede, H-G Genieser and 2 more

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Complex roles of cAMP-PKA-CREB signaling in cancer.Experimental hematology & oncology · 2020
    Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

S HusebyDepartment of Biomedicine, University of Bergen, Jonas Lies vei 91, 5009 Bergen, Norway.
G Gausdal
T J Keen
E Kjærland
C Krakstad
L Myhren
K Brønstad
C Kunick
F Schwede
H-G Genieser
R Kleppe
S O Døskeland
University of Bergen · NOBiolog Life Science Institute · DEHaukeland University Hospital · NOTechnische Universität Braunschweig · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IPC-81 cell line is derived from the transplantable BNML model of acute myelogenic leukemia (AML), known to be a reliable predictor of the clinical efficiency of antileukemic agents, like the first-line AML anthracycline drug daunorubicin (DNR). We show here that cAMP acted synergistically with DNR to induce IPC cell death. The DNR-induced death differed from that induced by cAMP by (1) not involving Bim induction, (2) being abrogated by GSK3β inhibitors, (3) by being promoted by the HSP90/p23 antagonist geldanamycin and truncated p23 and (4) by being insensitive to the CRE binding protein (CREB) antagonist ICER and to cyclin-dependent protein kinase (CDK) inhibitors. In contrast, the apoptosis induced by cAMP correlated tightly with Bim protein expression. It was abrogated by Bim (BCL2L11) downregulation, whether achieved by the CREB antagonist ICER, by CDK inhibitors, by Bim-directed RNAi, or by protein synthesis inhibitor. The forced expression of BimL killed IPC-81(WT) cells rapidly, Bcl2-overexpressing cells being partially resistant. The pivotal role of CREB and CDK activity for Bim transcription is unprecedented. It is also noteworthy that newly developed cAMP analogs specifically activating PKA isozyme I (PKA-I) were able to induce IPC cell apoptosis. Our findings support the notion that AML cells may possess targetable death pathways not exploited by common anti-cancer agents.

Indexed as

ApoptosisTranscription, GeneticActivating Transcription Factor 2AnimalsAntibiotics, AntineoplasticApoptosis Regulatory ProteinsBcl-2-Like Protein 11BenzoquinonesCell Line, TumorCyclic AMPCyclic AMP-Dependent Protein Kinase Type ICyclic AMP-Dependent Protein Kinase Type IICyclic AMP Response Element ModulatorCyclin-Dependent KinasesDaunorubicinDrug SynergismActivating Transcription Factor 2Antibiotics, AntineoplasticApoptosis Regulatory ProteinsBcl2l11 protein, ratBcl-2-Like Protein 11BenzoquinonesCrem protein, ratCyclic AMPCyclic AMP-Dependent Protein Kinase Type ICyclic AMP-Dependent Protein Kinase Type IICyclic AMP Response Element ModulatorCyclin-Dependent KinasesDaunorubicingeldanamycinGlycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, ratLactams, MacrocyclicMembrane ProteinsProto-Oncogene Proteins

Identifiers

PMID22158476
PMCPMC3252733
OpenAlexW2060737106

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.